AGI REPORTS IBS TRIAL DATA

A A

AGI Therapeutics has announced preliminary results from Phase II trials of two of its treatments.

The company reported that results for arverapamil, which is aimed at patients suffering from irritable bowel syndrome (IBS), were positive. Results for espindolol, which is targeted at dyspepsia, were less conclusive. Espindolol is part of a separate trial for the treatment of IBS.